Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4593543 | 0.82 | GAA (0.37) | GAADAOALDH1A1GFERKMT2A | |
| SCHEMBL4593415 | 0.76 | DAO (0.38) | GAAP2RX7DAOALDH1A1KDM4E | |
| SCHEMBL19887771 | 0.74 | P2RX7 (0.40) | P2RX7ALDH1A1 | |
| SCHEMBL19887751 | 0.74 | P2RX7 (0.40) | P2RX7ALDH1A1 | |
| SCHEMBL14626458 | 0.74 | GAA (0.40) | GAADAOALDH1A1KDM4EGFER | |
| SCHEMBL2046069 | 0.73 | DAO (0.57) | GAADAOKMT2A | |
| SCHEMBL2045392 | 0.72 | GAA (0.42) | GAADAOKDM4EKMT2A | |
| SCHEMBL21981585 | 0.71 | DAO (0.51) | GAADAOALDH1A1KDM4EKMT2A | |
| SCHEMBL5030980 | 0.71 | ALDH1A1 (0.33) | P2RX7ALDH1A1 | |
| SCHEMBL12810062 | 0.69 | P2RX7 (0.33) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910391-A1 | PROCESSES FOR PREPARING PYRAZOLE-O-GLYCOSIDE DERIVATIVES AND NOVEL INTERMEDIATES OF SAID PROCESSES | Boehringer Ingelheim International GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| US-20080020987-A1 | Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes | AJINOMOTO CO., INC. (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080020987-A1 | Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes | AJINOMOTO CO., INC. (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080020987-A1 | Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes | AJINOMOTO CO., INC. (JP) | 2008-01-24 | — | — | US | disclosed |
| WO-2007010015-A1 | PROCESSES FOR PREPARING PYRAZOLE-O-GLYCOSIDE DERIVATIVES AND NOVEL INTERMEDIATES OF SAID PROCESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007010015-A1 | PROCESSES FOR PREPARING PYRAZOLE-O-GLYCOSIDE DERIVATIVES AND NOVEL INTERMEDIATES OF SAID PROCESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080020987-A1 | Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes | CYP4B1, CYP1B1, CYP11B1 | GAA 368/4885P2RX7 111/4885DAO 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.